Ken Griffin Lyra Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 21,100 shares of LYRA stock, worth $3,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,100

Previous 23,400 9.83%

Holding current value

$3,587

Previous $6,000 16.67%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.26 - $6.25 $112,765 - $2.71 Million	433,715 Added 10.0%	4,772,816 $1.34 Million
Q1 2024 May 15, 2024	BUY	$4.55 - $6.53 $6.72 Million - $9.65 Million	1,477,846 Added 51.65%	4,339,101 $27 Million
Q4 2023 Feb 14, 2024	BUY	$2.82 - $5.24 $35,788 - $66,500	12,691 Added 0.45%	2,861,255 $15 Million
Q3 2023 Nov 14, 2023	SELL	$2.95 - $4.8 $1,811 - $2,947	-614 Reduced 0.02%	2,848,564 $11.1 Million
Q2 2023 Aug 14, 2023	BUY	$1.98 - $4.33 $5.63 Million - $12.3 Million	2,841,244 Added 35810.99%	2,849,178 $11.7 Million
Q1 2023 May 15, 2023	SELL	$1.95 - $3.09 $33,818 - $53,589	-17,343 Reduced 68.61%	7,934 $15,000
Q4 2022 Feb 14, 2023	SELL	$2.44 - $5.42 $28,935 - $64,275	-11,859 Reduced 31.93%	25,277 $79,000
Q3 2022 Nov 14, 2022	BUY	$4.95 - $6.6 $183,823 - $245,097	37,136 New	37,136 $186,000
Q1 2022 May 16, 2022	SELL	$3.5 - $5.36 $46,382 - $71,030	-13,252 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.22 - $9.41 $55,923 - $124,701	13,252 New	13,252 $57,000
Q3 2021 Nov 15, 2021	SELL	$6.06 - $9.43 $117,448 - $182,762	-19,381 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.91 - $12.59 $133,922 - $244,006	19,381 New	19,381 $155,000
Q3 2020 Nov 16, 2020	SELL	$10.61 - $13.96 $2.71 Million - $3.57 Million	-255,794 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.91 - $18.56 $2.79 Million - $4.75 Million	255,794 New	255,794 $2.9 Million

Others Institutions Holding LYRA

# of Institutions

Shares Held

32.3M

Call Options Held

21.1K

Put Options Held

400

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $5.41M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account